Beam Therapeutics rises as FDA lifts hold on cancer drug study

Beam Therapeutics

02/12/2022 12:58

** Shares of Beam Therapeutics Inc  BEAM.O  rise 2.5% to $47
before the bell
    ** The drug developer says U.S. FDA has lifted the clinical
hold and cleared its experimental therapy being developed to
treat patients with a type of blood cancer for study
 urn:newsml:reuters.com:*:nGNX6mBwnW
    ** We look forward to providing updates on next steps for
the program in 2023 - BEAM
    ** Up to Thursday's close, stock down ~42% YTD 
 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))